Dr. Geoffrey Kim is the co-founder and Chief Executive Officer of Pi Health, a healthcare technology company launched in 2021 whose mission is to drive innovation to enable patients all over the world to have equal access to the highest quality of care and research. He has over 25 years of experience in oncology drug development, regulation, and precision medicine.

As Vice President of Applied Innovation at BeiGene, Geoff established an innovative team focused on increasing patient access to clinical trials and novel cancer therapies. His group pioneered methodologies to integrate diverse datasets and drive pipeline advancement through data analysis and strategic development, while simultaneously laying the groundwork for the establishment of Pi Health through the invention of the FICS technology platform.

Prior to his role at BeiGene, Geoff served as Vice President of Oncology Regulatory Science and Strategy at AstraZeneca. He led the regulatory function and shaped regulatory strategies for oncology treatments in a complex, evolving landscape, leading to the approvals of acalabrutinib in CLL and trastuzumab-deruxtecan in metastatic breast cancer. Previously, as Vice President of Strategic Combinations, he defined development and commercialization approaches for immuno-oncology combinations, external partnerships, and women’s cancers, including the strategic oversight of IO-based combination such as the combination of durvalumab and olaparib in multiple solid tumors.

Earlier in his career, Geoff played a pivotal role in oncology regulation at the U.S. Food and Drug Administration (FDA). As Deputy Director of the Oncology Center of Excellence, he helped launched the OCE under the provisions of the 21st Century Cures Act and laid the framework for the unified review of drugs, devices, and biologics that are intended to cure, treat, and prevent cancer. Geoff was also director of the Division of Oncology Products 1 in the Office of Hematology Oncology Products, where he oversaw the evaluation and regulation of oncology drug products for breast, genitourinary and gynecologic cancers and approved practice changing medicines such as CDK4/6 inhibitors for breast cancers, PARP inhibitors for ovarian cancers, and immunotherapy for genitourinary malignancies. He was also involved with numerous cross-functional working groups, developing policies pertaining to in-vitro companion diagnostics, combination products, and therapy dose optimization strategies for cancer medicines.

Dr. Kim completed his medical oncology fellowship at the National Cancer Institute (NCI) where he was active in both laboratory and clinical research in molecular signaling and ovarian cancer. He received his medical degree from New York Medical College and completed his residency in internal medicine at the Montefiore Medical Center.